This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Dec 23;363(26):2559-61.

doi: 10.1056/NEJMe1012149.

Therapeutic potential of oral factor Xa inhibitors

PMID: 21175319
DOI: 10.1056/NEJMe1012149

Editorial

Therapeutic potential of oral factor Xa inhibitors

Elaine M Hylek. N Engl J Med. 2010.

. 2010 Dec 23;363(26):2559-61.

doi: 10.1056/NEJMe1012149.

Author

PMID: 21175319
DOI: 10.1056/NEJMe1012149

No abstract available

PubMed Disclaimer

Comment on

Oral rivaroxaban for symptomatic venous thromboembolism.
EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. EINSTEIN Investigators, et al. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3. N Engl J Med. 2010. PMID: 21128814 Clinical Trial.
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Lassen MR, et al. N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885. N Engl J Med. 2010. PMID: 21175312 Clinical Trial.

Similar articles

Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Lee S, White CM. Lee S, et al. Conn Med. 2012 Jan;76(1):39-42. Conn Med. 2012. PMID: 22372178 Review. No abstract available.
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Friedman RJ. Friedman RJ. Orthopedics. 2011 Oct;34(10):795-804. doi: 10.3928/01477447-20110826-24. Orthopedics. 2011. PMID: 21956181 Review.
Rivaroxaban for thromboprophylaxis.
Schuman EP. Schuman EP. N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. doi: 10.1056/NEJMc081524. N Engl J Med. 2008. PMID: 19005203 No abstract available.
Rivaroxaban for thromboprophylaxis.
ten Cate H, Hamulyak K. ten Cate H, et al. N Engl J Med. 2008 Nov 13;359(20):2174-5; author reply 2176. N Engl J Med. 2008. PMID: 19009676 No abstract available.
Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Perzborn E. Perzborn E. Hamostaseologie. 2009 Aug;29(3):260-7. Hamostaseologie. 2009. PMID: 19644596

See all similar articles

Cited by

Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
Jain N, Reilly RF. Jain N, et al. Clin J Am Soc Nephrol. 2019 Feb 7;14(2):278-287. doi: 10.2215/CJN.02170218. Epub 2018 May 25. Clin J Am Soc Nephrol. 2019. PMID: 29802125 Free PMC article. Review.
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol.
Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, Williams T, Celermajer D, Sahhar J, Wong PK, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, Staples M, Buchbinder R, Nikpour M. Calderone A, et al. BMJ Open. 2016 Dec 8;6(12):e011028. doi: 10.1136/bmjopen-2016-011028. BMJ Open. 2016. PMID: 27932335 Free PMC article. Clinical Trial.
Oral anticoagulant-associated intracerebral hemorrhage.
Cervera A, Amaro S, Chamorro A. Cervera A, et al. J Neurol. 2012 Feb;259(2):212-24. doi: 10.1007/s00415-011-6153-3. Epub 2011 Jul 5. J Neurol. 2012. PMID: 21748282 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.